| Project/Area Number |
15590039
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY |
|---|
Principal Investigator |
UENO Masaharu Toyama Medical and Pharmaceutical University, Faculty of Pharmaceutical Sciences, professor, 薬学部, 教授 (40080197)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAYASHI Kyouko Toyama Medical and Pharmaceutical University, Faculty of Medicine, research associate, 医学部, 助手 (60110623)
SUZUKI Masao Toyama Medical and Pharmaceutical University, Institute for Form and function, researcher, 研究職
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2004: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2003: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | membrane protein / liposomes / artificial membrane vaccine / CV-1 cell / influenza virus / immunoprecipitation / immunoactivity / adjuvant / 膜たんぱく質 / 膜間移行 / 免疫能 / 中和抗体 / HA / NA / 抗体産生能 / MDP誘導体 |
|---|
| Research Abstract |
Recentlyy it has been reported that the various membrane proteins are transferred spontaneously from living cell membranes to liposomal membranes. We adopted the phenomenon in developing liposome vaccine against influenza virus. First, we studied viral protein transfer from influenza virus-infected cells to liposomes. Next, biological activity of the liposome vaccine was examined.
The membrane proteins were recovered on the liposomes in both cases : One is direct transfer of protein in the condition of coexisting of donor cells and acceptor liposomes ; the other is protein transfer from the sorting buffer to the liposomes, in which buffer virus-infected cells were incubated for 1 hour without liposomes followed by adding liposomes after removing cells. Immunoprecipitation and immunoblotting experiments showed the transfer of viral protein from influenza virus-infected CV-1 celles to liposomes.
The antigenic protein-incorporated liposomes were inoculated to BALB/c mice as an artificial membrane vaccine or liposome vaccine. Immunoactivity of the liposome vaccine was almost equivalent to that of inactivated virus. B-30 MDP (6-o-(2-tetradecyl hexadecanoyl)-N-acetylmuramyl-L-aranyl-isoglutamine) as an adjuvant enhanced strongly immunoactivity.
|
